Ovarian Cancer

Phase II trial of squalamine shows encouraging results

Published in Cancer Weekly, June 18th, 2002

Genaera Corporation (GENR) announced the presentation of encouraging results for its antiangiogenic drug, squalamine, in its phase II recurrent advanced ovarian cancer clinical trial, at the meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.

The ongoing phase II clinical trial in recurrent advanced ovarian cancer is a multicenter, open label design, evaluating squalamine in combination with carboplatin. In this study, 35% of evaluable patients (9 of 26) have had an objective response to the study drug regimen of squalamine and carboplatin. Best response to therapy has included five complete responses, and four partial responses. Four of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-06-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry